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Abstract 
Background: Emergence of high-grade sulfadoxine-pyrimethamine (SP) resistance in parts of Africa has led to grow-
ing concerns about the efficacy of intermittent preventive treatment of malaria during pregnancy (IPTp) with SP. The 
incremental cost-effectiveness of intermittent screening and treatment (ISTp) with artemether-lumefantrine (AL) as an 
alternative strategy to IPTp-SP was estimated followed by a simulation of the effects on cost-effectiveness of decreas-
ing efficacy of IPTp-SP due to SP resistance. The analysis was based on results from a multi-centre, non-inferiority trial 
conducted in West Africa.
Methods: A decision tree model was analysed from a health provider perspective. Model parameters for all trial 
countries with appropriate ranges and distributions were used in a probabilistic sensitivity analysis. Simulations were 
performed in hypothetical cohorts of 1000 pregnant women who received either ISTp-AL or IPTp-SP. In addition 
a cost-consequences analysis was conducted. Trial estimates were used to calculate disability-adjusted-life-years 
(DALYs) for low birth weight and severe/moderate anaemia (both shown to be non-inferior for ISTp-AL) and clinical 
malaria (inferior for ISTp-AL). Cost estimates were obtained from observational studies, health facility costings and 
public procurement databases. Results were calculated as incremental cost per DALY averted. Finally, the cost-effec-
tiveness changes with decreasing SP efficacy were explored by simulation.
Results: Relative to IPTp-SP, delivering ISTp-AL to 1000 pregnant women cost US$ 4966.25 more (95 % CI US$ 
3703.53; 6376.83) and led to a small excess of 28.36 DALYs (95 % CI −75.78; 134.18), with LBW contributing 81.3 % of 
this difference. The incremental cost-effectiveness ratio was −175.12 (95 % CI −1166.29; 1267.71) US$/DALY averted. 
Simulations show that cost-effectiveness of ISTp-AL increases as the efficacy of IPTp-SP decreases, though the specific 
threshold at which ISTp-AL becomes cost-effective depends on assumptions about the contribution of bed nets to 
malaria control, bed net coverage and the willingness-to-pay threshold used.
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Background
Malaria in pregnancy (MiP) is associated with poor 
health outcomes in the mother and child, primarily dur-
ing the first and second pregnancies. The most notable 
adverse health outcomes in moderate or high transmis-
sion settings include maternal anaemia, perinatal mortal-
ity and low birth weight (LBW) [1].
The approach to MiP prevention currently recom-
mended by WHO consists of long-lasting insecticide 
treated bed nets (LLIN) and provision of sulfadoxine-
pyrimethamine (SP) as intermittent preventive treatment 
(IPTp-SP) at each scheduled antenatal care (ANC) visit 
from the beginning of the second trimester until delivery 
[2, 3]. By clearing existing infections caused by drug-sen-
sitive parasites as well as preventing incident infections, 
IPTp-SP reduces the risk of maternal anaemia, LBW and 
neonatal mortality [4]. Currently, 39 countries in malaria 
endemic sub-Saharan Africa have an IPTp policy [5]. 
However, analysis of national survey data from 27 coun-
tries from 2009 to 2011 estimated that despite high ANC 
coverage (≥2 visits, 75.1 %), only 21.5 % of the total births 
at risk of malaria were born to mothers who received 
IPTp-SP [6].
Over the last decade, the emergence and spread of 
high-level parasite resistance to SP in eastern and south-
ern Africa has led to growing concerns about the effec-
tiveness of IPTp-SP [7–10], although the loss of efficacy 
may be lower in pregnant women than in children under 
five years of age [11]. SP resistance occurs through point 
mutations in the genes encoding the target enzymes of 
SP, dihydropteroate synthase (dhps) and dihydrofolate 
reductase (dhfr) with prevalence of different mutant 
alleles varying throughout Africa. In areas with  >90  % 
prevalence of the quintuple mutation, named after its its 
molecular maker “K540E”, there was continued beneficial 
impact of IPTp-SP on birthweight and maternal haemo-
globin levels. However, IPTp-SP effectiveness becomes 
threatened in areas where prevalence of the sextuple 
Pfdhps-A581G mutation exceeds 10 %, such as northern 
Tanzania, western Kenya and southern Uganda [9, 10, 
12–15]. For such areas there is a criticial need to evalu-
ate alternative drugs to replace SP or alternative strate-
gies using a diagnostic based test-and-treat intervention 
to replace IPTp. Trials of mefloquine and azithromycin 
with chloroquine showed that these alternatives were 
not sufficiently well tolerated or efficacious in pregnant 
women to be used for IPTp [16, 17]. IPTp with dihydroar-
temisinin/piperaquine has recently shown more encour-
aging results in Kenya and Uganda [13, 18], but there are 
concerns about using artemisinin combinations for wide-
spread prophylaxis. Intermittent screening of women at 
each ANC visit with a rapid diagnostic test for malaria 
(RDT) and treatment of those with a positive result with 
an artemisin-based combination therapy (ACT) (ISTp) 
is a potential alternative approach to IPTp-SP in areas 
where the latter is no longer effective. A pilot study of 
this approach conducted in Ghana showed that ISTp was 
non-inferior to IPTp-SP in preventing LBW and mater-
nal anaemia [19]. To confirm this result a non-inferiority 
trial which compared ISTp with artemether-lumefantrine 
(AL) versus IPTp-SP was conducted in four countries in 
West Africa (Burkina Faso, Ghana, Mali and The Gam-
bia) [20]. The trial found ISTp-AL to be non-inferior to 
IPTp-SP with respect to all the primary outcomes, which 
were risk of LBW, mean maternal haemoglobin concen-
tration prior to delivery and the prevalence of placental 
malaria [20]. However, the incidence of clinical attacks of 
malaria was significantly higher in women who received 
ISTp-AL than in those who received IPTp-SP.
Policymakers need to know the costs and cost-effec-
tiveness of ISTp-AL and IPTp-SP as well as their clinical 
impact in order to inform any decisions about a change 
of strategy in the management of MiP. It was anticipated 
that the cost of ISTp-AL would be higher than IPTp-SP 
because (i) every woman receives an RDT (which itself is 
slightly more expensive than SP), (ii) it requires a more 
expensive drug to be administered to women screened 
as positive for malaria parasites, and iii) the procedure is 
more time-consuming. ISTp-ALis likely to be less effec-
tive where IPTp SP works well because RDTs have a low 
sensitivity [13] and women derive prophylactic benefit 
from IPTp-SP even if they are uninfected at the time of 
drug administration. For these reasons, the objective of 
this analysis was to estimate the incremental cost effec-
tiveness of ISTp-AL versus IPTp-SP and then to simulate 
the effects on cost effectiveness of changes in SP efficacy 
due to spread of resistance. The cost effectiveness model 
incorporated the primary and key secondary endpoints 
published by Tagbor et  al. [20]. In addition a cost-con-
sequences analysis (CCA) was conducted in order to: (1) 
identify and consider effects that cannot easily be trans-
lated into health outcomes and (2) to report outcomes 
Conclusions: At SP efficacy levels currently observed in the trial settings it would not be cost-effective to switch 
from IPTp-SP to ISTp-AL, mainly due to the substantially higher costs of ISTp-AL and limited difference in outcomes. 
The modelling results indicate thresholds below which IPT-SP efficacy must fall for ISTp-AL to become a cost-effective 
option for the prevention of malaria in pregnancy.
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and costs separately, instead of aggregating them into a 
composite measure such as DALYs or QALYs and incre-
mental cost-effectiveness ratios (ICERs) [21].
Methods
Trial setting, population, procedures and analysis
The trial (ClinicalTrials.gov reference: NCT01084213) 
enrolled a total of 5354 women in their first or second 
pregnancy at five sites in Burkina Faso, Ghana, Mali and 
The Gambia, with seasonal moderate or high malaria 
transmission and a prevalence of the K540E haplo-
type <1 % [14, 20]. All participants received an LLIN at 
enrolment, and then received either IPTp-SP or ISTp-AL 
at ANC contacts during their pregnancies. The primary 
objective of the trial was to establish whether ISTp-AL 
was non-inferior to, or in other words not worse by a 
clinically important amount than IPTp-SP in terms of 
preventing the following primary outcomes: (1) LBW 
(non-inferiority odds ratio (OR) margin  <1.263), (2) 
maternal haemoglobin (Hb) concentration prior to deliv-
ery (non-inferiority margin  <0.2  g/dl Hb concentration 
reduction) and (3) the prevalence of placental malaria 
(non-inferiority OR margin  <1.286) [22]. More details 
on the trial population, procedures and data analysis are 
provided in Tagbor et al. [20].
Outcomes
For the analysis described below, model outcomes 
were selected from the outcome categories affect-
ing the mother or the offspring based on (1) clinical 
and economic importance, and (2) availability of dis-
ability weights to calculate disability-adjusted-life-years 
(DALYs). Based on these criteria, LBW, moderate to 
severe anaemia prior to delivery (both primary trial out-
comes for which ISTp-AL was shown to be non-inferior) 
and clinical malaria (defined as an unscheduled clinic 
visit due to illness with a positive blood smear,- a sec-
ondary trial outcome, for which ISTp-AL was shown to 
be inferior to IPTp-SP) were included as model outcomes 
in the cost-effectiveness analysis as well as in the subse-
quent resistance modelling. The total DALYs in each arm 
were calculated by summing the DALYs from the three 
outcomes, as disability weights of concurring events (i.e. 
malaria infection and anaemia) are unknown. In addi-
tion, adverse events measured in the trial as well as intan-
gible outcomes, such as the value of treating according to 
a test result rather than presumptively, were included in a 
cost-consequences analysis.
Costs
The incremental fixed and variable cost to the health 
provider of delivering the interventions including and 
excluding the costs arising from the consequences of 
MiP (i.e. clinical malaria disease, moderate/severe anae-
mia and LBW) was calculated. Household costs were 
excluded since both interventions would be part of rou-
tine ANC visits, provided free of charge in most settings 
in sub-Saharan Africa and, therefore, not expected to dif-
fer between the interventions.
Economic costs were calculated and expressed in con-
stant 2012 US$, using the local consumer price index 
[23] and average 2012 exchange rates [24]. Cost data 
collection comprised (1) health facility costing studies 
in the Ségou region, Mali (N = 4) and in the Upper East 
Region, Ghana (N = 4) and (2) two observational studies 
of the time nurses took to administer ISTp and IPTp in 
Ghana (NISTp = 18; NIPTp = 20) and Malawi (NISTp = 30; 
NIPTp  =  18), conducted by the Economics Working 
Group of the Malaria in Pregnancy Consortium. All cost 
data collection was approved by the Ethics Committee 
of the London School of Hygiene and Tropical Medicine 
and by the relevant ethics committees in the countries 
where cost data were collected. Informed consent was 
obtained from each participant being observed. For more 
details on cost data collection methods see Additional 
file 1: Appendix S1.
Analysis and model
The cost-effectiveness analysis was conducted from the 
health provider perspective. To account for the effects of 
a potential increase in SP resistance, the cost effective-
ness of ISTp-AL versus IPTp-SP for decreasing efficacy 
of SP was simulated. In addition, the effects of reduc-
ing the costs of RDTs and AL by one half were analysed. 
Separate, but structurally identical decision tree models 
were developed for each outcome (see Fig.  1 for LBW). 
A lifetime horizon was adopted to show the lifelong (dis-
counted) mortality effects of the consequences of MiP.
DALYs were estimated using disability weights from 
the Global Burden of Disease Study (GBD) 2010 and 2004 
[25, 26], applying local life expectancies, no age weight-
ing, and discounting at 3 %. For more details on the cal-
culation of DALYs, see Additional file 1: Appendix S1 [25, 
26].
The incremental cost-effectiveness ratio (ICER) was 
calculated for a hypothetical cohort of 1000 women 
by dividing the incremental cost of the intervention by 
the incremental DALYs averted [(CostsISTp-AL-Cost-
sIPTp-SP)—Cost from health consequences from MiP/
(DALYIPTp-SPp-DALYISTp-AL)].
The CCA separated costs and consequences into four 
categories, calculated per 1000 women where applica-
ble: (i) costs, (ii) measurable outcomes contributing to 
DALYs, (iii) measurable outcomes that do not contribute 
to DALYs, and (iv) non measurable outcomes, such as the 
value of not giving medicines to all pregnant women. The 
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costs were calculated including and excluding the costs 
associated with the health consequences, and presented 
with 95 % confidence intervals based on percentiles.
To illustrate the uncertainty of all estimates simultane-
ously we conducted a probabilistic sensitivity analysis 
(PSA) with 10,000 iterations, producing a point estimate 
and 95 % confidence interval based on percentiles for the 
differences in costs and effects, and an average ICER. Cost-
effectiveness guidelines were used to assign an appropri-
ate distribution to each parameter [27] (Table 1). The PSA 
results were plotted on the cost effectiveness plane and 
assessed against three frequently applied policymaker 
willingness-to-pay (WTP) thresholds, referred to as low 
(US$ 39.72), middle (US$ 238.33) and high (US$ 861.33), 
respectively. The low and middle threshold are the his-
toric WHO thresholds of US$ 25 and US$ 150 adjusted for 
inflation [28], while the high threshold is the unweighted 
mean GDP per capita calculated across the four countries 
[29]. No deterministic sensitivity analysis was conducted, 
as only unrealistically large changes to a single parameter 
could lead to a conclusion-changing base case ICER.
The impact of different levels of SP resistance on the 
ICER was subsequently modelled, by changing the effi-
cacy of IPTp-SP while holding the efficacy of ISTp-AL 
constant as measured in the trial. The measured risk 
of the model outcomes (LBW, severe/moderate anae-
mia and clinical malaria) in the IPTp-SP arm of the trial 
was assumed to be the maximum possible efficacy and 
labelled as 100  %. All trial participants were assumed 
to have slept under an LLIN. Details of how SP resist-
ance affects IPTp-SP efficacy are not clearly understood, 
therefore we assumed a linear relationship between 
decreasing IPTp-SP efficacy and outcomes. Data from 
the Cochrane review by Radeva-Petrova et al. [30] (com-
paring IPTp-SP with placebo or no intervention) were 
used to calculate the extrapolated risk of the model out-
comes in the IPTp-SP group by percentage point change 
in efficacy, from 100  % (maximum) to 0  % (minimum). 
As the Cochrane review authors were unable to stratify 
IPTp efficacy by bed net use, the effect of bed nets on 
these modelled outcomes was explored in three scenar-
ios, by assuming: (1) bed nets have no effect and the full 
extrapolated risk was attributable to IPTp-SP (used as 
the starting point for simulation only), (2) bed nets bear 
1/2 and (3) 2/3 of the burden and, therefore, only 1/2, or 
1/3, respectively, of the extrapolated risk of the model 
outcomes was attributable to IPTp-SP. Subsequently, the 
incremental costs, incremental DALYs and ICERs com-
paring ISTp-AL with IPTp-SP at each percentage point of 
decreasing SP efficacy for each of the three bed net sce-
narios were calculated.
Finally, these hypothetical results were used to calcu-
late the threshold level of SP efficacy at which ISTp-AL 
would become cost effective, stratified by WTP and 
assumption about the contribution of bed nets. For more 
details on how the resistance modelling was conducted, 
please refer to Additional file 1: Appendix S1. All resist-
ance simulations included the costs arising from health 
consequences of MiP and at bed net coverage levels esti-
mated in the most recent Demographic and Health Sur-
veys in the four trial countries (unweighted average of 
47.7 % across the four countries).
Analysis of international procurement databases indi-
cated an overall downwards trend in the unit cost of 
RDTs and AL from 2010 to 2014. Therefore, the impact of 
reducing these commodity costs by 50 % (with the stand-
ard error held constant) on the ICER and in the resist-
ance analysis was explored.
To be able to show simultaneously how the cost effec-
tiveness changes by level of SP efficacy, assumption of the 
contribution of bed nets and bed net coverage, we used a 
net monetary benefit (NMB) function instead of the ICER, 
because (a) the simulated results cannot easily be depicted 
when the denominator of a ratio approaches 0 and (b) 
because NMB includes the WTP threshold in the formula. 
The formula for NMB is as follows: NMB  =  (∆DALY 
averted x WTP)-∆Costs. When using NMB, an interven-
tion becomes cost effective when the NMB is ≥0.
Stata (version 12, StataCorp, College Station, Texas) 
was used to analyse the observational data whilst the 
international procurement data, the health facility costs 
and the decision tree model were analysed in Excel 
(Microsoft Office 2013), the latter also using Visual Basic 
for Applications.
LBW
151 (95% CI 137-167) babies
IPTp-SP
1000 women
No LBW
849 (95% CI 833-863) babies
LBW
156 (95% CI 141-172) babies
ISTp-AL
1000 women
No LBW
844 (95% CI 828-859) babies
*idencal structure for moderate/severe anaemia and maternal malaria
Fig. 1 The decision tree. The decision tree model illustrates the 
example for LBW. All numbers represent the results published in 
Tagbor et al. [20]. The same structure was used for moderate/severe 
anaemia and clinical malaria. IPTp-SP intermittent preventive treat-
ment with sulfadoxine-pyrimethamine; ISTp-AL intermittent screening 
and if positive followed by treatment with arthemether-lumefantrine; 
LBW low birth weight
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Table 1 Input variables for the cost consequence analysis and the base case and probabilistic cost-effectiveness analysis
Parameter Base case Low High Distribution for PSA Source
Cost estimates
Health care worker time cost
 Time nurses take to provide 1 dose IPTp-SP in 
Ghana (min)
95 % CI (N = 18)
18.00 15.54 20.46 Gamma Observational study of trial participants: 
(Ghana)
 Time nurses take to provide 1 dose IPTp-SP in 
Malawi (min)
95 % CI (N = 18)
3.55 2.58 4.52 Gamma Observational study of trial participants: 
(Malawi)
 Time nurses take to provide 1 admin ISTp-AL in 
Ghana (min)
95 % CI (N = 3) if RDT neg
13.67 9.87 17.46 Gamma Observational study of trial participants: 
(Ghana)
 Time nurses take to provide 1 admin ISTp-AL in 
Ghana (min)
95 % CI (N = 13) if RDT pos
24.29 21.43 27.16 Gamma Observational study of trial participants: 
(Ghana)
 Time nurses take to provide 1 admin ISTp-AL in 
Malawi (min)
95 % CI (N = 22) if RDT neg
5.67 4.91 6.44 Gamma Observational study of trial participants: 
(Malawi)
 Time nurses take to provide 1 admin ISTp-AL in 
Malawi (min)
95 % CI (N = 8) if RDT pos
12.65 11.52 13.78 Gamma Observational study of trial participants: 
(Malawi)
 Number of administrations in IPTp-SP arm 2.06 – – Point estimate [20]
 Number of administrations in ISTp-AL arm 2.76 – – Point estimate [20]
 % of administrations of ISTp with a positive RDT 
result
24.7 % Point estimate [20]
 Nurses’ monthly cost of labour, 95 % CI (US$ 2012) 346.33 164.83 527.84 Gamma Countries MoHa
Drug costs
 Average SP price per administration, 95 % CI  
(US$ 2012)
0.20 0.16 0.27 Lognormal International procurement databasesb
 Average AL price per administration, 95 % CI  
(US$ 2012)
2.39 1.71 3.06 Lognormal International procurement databasesb
 Average RDT price per administration, 95 % CI 
(US$ 2012)
0.81 0.58 0.90 Lognormal International procurement databasesb
Costs from consequences
 Incremental days in hospital comparing LBW 
versus NBW (days)
0.64 0.40 0.89 Normal Trial post partum follow up data
 Cost per paediatric IP day (excluding medical  
supplies) (US$ 2012)
63.46 31.73 95.19 Gamma Health facility costings (Ghana, Mali)
 Cost per OP visit (excluding medical supplies) 
(US$ 2012)
11.76 8.45 15.06 Gamma Health facility costings (Ghana, Mali)
 Cost per IP day (excluding medical supplies)  
(US$ 2012)
35.25 17.63 52.88 Gamma Health facility costings (Ghana, Mali)
Daly calculations
 Discount rate r 0.03 0.00 0.05 Point estimate Assumption
 Average age (years)c 20.40 – – Point estimate [20]
 Life expectancy women aged 20–24 years 50.12 45.11 55.13 Lognormal GBD study 2010d [32]
 Life expectancy at birth 61.56 56.86 66.31 Lognormal GBD study 2010d [32]
 Length disability—malaria during pregnancy 
(3.5 days, range 2–6)
0.010 0.005 0.016 Gamma Assumption
 Length disability—malaria related anaemia 
(21 days, range 14–42)
0.06 0.04 0.12 Gamma Price et al. [33]
 Length disability—LBW (years) 57.96 52.91 64.80 Lognormal GBD 2010 study [32]
 Disability weight infectious disease severe acute 
episode (95 % CI)
0.21 0.14 0.30 Lognormal GBD 2010 study [25]
 Disability weight maternal anaemia: moderate 
(95 % CI)
0.06 0.04 0.09 Lognormal GBD 2010 study [25]
 Disability weight LBW 0.11 – – Point estimate GBD 2004 update (data from 1990) [26]
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Results
Consequences
Per 1000 women there were 151 (95 % CI 137;167) vs 156 
(95 % CI 141;172) LBW babies, 17 (95 % CI 12;25) vs 23 
(95 % CI 17;32) cases of severe or moderate anaemia and 
74 (95  % CI 61;92) vs 115 (95  % CI 96;144) episodes of 
clinical malaria at unscheduled visits in the IPTp-SP and 
ISTp-AL groups, respectively (Table 3). The total burden 
was estimated as 755.1 and 782.9 DALYs per 1000 women 
in the IPTp-SP and ISTp-AL arms, respectively (Table 3).
Table 1 continued
Parameter Base case Low High Distribution for PSA Source
Mortality estimates
 LBW attributable neonatal mortality risk % 6.93 4.36 9.50 Beta Marchant et al. [34]
 CFR malaria during pregnancy % 0.0033 0.0026 0.0045 Beta Sicuri et al. [35]
 CFR moderate/severe anaemia in pregnancy % 0.01 – – Beta Brabin et al. [36]
Measures of effect (trial conducted in Primi- and secundigravidae only)
Low birth weight
 LBW risk IPTp-SP arm per 1000 women 151.2 136.8 166.8 Beta [20]
 LBW risk ISTp-AL arm per 1000 women 155.8 141.3 171.5 Beta [20]
Moderate/severe maternal anaemia (<8, 7, or 6 g/dl)
 Moderate/severe anaemia risk at last ANC visit 
IPTp-SP arm per 1000 women
16.9 11.6 24.7 Beta [20]
 Moderate/severe anaemia risk at last ANC visit 
ISTp-AL arm per 1000 women
23.1 16.8 31.7 Beta [20]
Episodes of clinical malaria
 0 episode clinical malaria IPTp-SP arm per  
1000 women
932.41 922.26 941.33 Dirichlet [20]
 1 episode clinical malaria IPTp-SP arm per  
1000 women
61.99 53.45 71.78 Dirichlet [20]
 2 episodes clinical malaria IPTp-SP arm per  
1000 women
5.6 3.38 9.27 Dirichlet [20]
 3 episodes clinical malaria IPTp-SP arm per  
1000 women
0.4 0.36 0.44 Dirichlet [20]
 0 episode clinical malaria ISTp-AL arm per  
1000 women
899.85 887.88 910.67 Dirichlet [20]
 1 episode clinical malaria ISTp-AL arm per  
1000 women
84.08 74.14 95.21 Dirichlet [20]
 2 episodes clinical malaria ISTp-AL arm per  
1000 women
14.95 10.98 20.32 Dirichlet [20]
 3 episodes clinical malaria ISTp-AL arm per  
1000 women
0.37 0.05 2.65 Dirichlet [20]
Measures of effect from cochrane review used for modelling of decreasing SP efficacy in IPTp arm
 Relative risk of LBW comparing IPTp-SP versus 
none or placebo
0.81 0.67 0.99 n/a [30]
 Relative risk of sev/mod anaemia comparing IPTp-
SP versus none or placebo
0.60 0.47 0.75 n/a [30]
 Relative risk of antenatal parasitaemia comparing 
IPTp-SP versus none or placebo
0.38 0.24 0.59 n/a [30]
Parameters are shown for all countries where the clinical trial was conducted in [32] (Burkina Faso, Ghana, Mali and The Gambia)
ANC antenatal care; CFR case fatality rate; DALY disability adjusted life years; HCW health care worker; IPTp-SP intermittent preventive treatment with sulfadoxine-
pyrimethamine; ISTp-AL intermittent screening and if positive followed by treatment with arthemether-lumefantrine; LBW low birth weight; MoH Ministry of Health; 
95 % CI 95 % confidence interval
a Salary scale and an average allowance package for nurses from Ministry of Health in Burkina Faso, Ghana, Mali and The Gambia for 2012
b Cost for dose of SP, AL and per RDT was calculated accounting for 5 % wastage, 10 % insurance and freight and 10 % in country transport
c Average age was used from the trial
d The life expectancy was analysed from the Global burden of disease 2010 database for the subgroups of interest (i.e. female only, age 20–24, trial countries and both 
gender, at birth, trial countries respectively)
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Costs
Table  2 shows the itemized cost results. The total cost 
(including health worker time and cost of supplies) per 
administration of IPTp-SP was US$ 0.79 (95  % CI 0.53; 
1.12). If screening was negative, the cost per administra-
tion of ISTp-AL was US$ 1.45 (95  % CI 1.12; 1.85) and 
US$ 4.06 (95  % CI 3.29, 4.97) if screening was positive 
(see Table 2).
The cost per outpatient visit for malaria treatment was 
US$ 11.78 (95 % CI 9.18; 14.68), per adult inpatient day 
US$ 35.27 (95 % CI 19.99; 55.07) and per paediatric inpa-
tient day US$ 63.51 (95 % CI 36.30; 99.27), the latter two 
excluding medical supplies. The final cost of health con-
sequences of MiP was estimated to be US$ 40.93 (95  % 
CI 19.52; 71.19) for the short-term consequences of LBW, 
US$ 10.15 (95  % CI 6.76; 15.17) for a moderate/severe 
anaemia case and US$ 13.71 (95 % CI 6.12; 24.65) for a 
clinical malaria case during pregnancy.
Table  3 shows the costs of administering the inter-
ventions to 1000 pregnant women, which amounted 
to US$ 1631.84 (95  % CI 1100.11; 2316.97) for IPTp-SP 
and US$ 5778.77 (95  % CI 4701.65; 7039.15) for ISTp-
AL, when excluding the costs arising from health conse-
quences of MiP. After including costs arising from health 
consequences it rose to US$ 9006.54 (95  % CI 5610.30; 
13,680.56) for IPTp-SP and US$ 13,972.79 (95  % CI 
10,199.65; 18,983.86) for ISTp-AL (Table 3). In summary, 
if 24.7 % of women screened in the ISTp-AL arm have a 
positive RDT test result, as measured in the trial, and if 
the costs of the consequences of MiP are included, ISTp-
AL costs on average around US$5 more per woman per 
pregnancy than IPTp-SP. If 10  % (as in The Gambia) or 
50 % (as in Ghana) of the RDT screenings were positive 
the costs per woman would amount to US$ 3.88 and US$ 
6.73, respectively.
Cost effectiveness analysis
Compared with IPTp-SP, delivering ISTp-AL to 1000 
pregnant women led to an excess of 27.8 DALYs, of which 
81.3 % were attributable to LBW, 5.9 % to severe/moder-
ate anaemia and 12.8 % to clinical malaria. With an incre-
mental cost of US$ 4929.0 per 1000 women, this produces 
an ICER of US$ −177.1/DALY averted (Table 4).
The negative ICER is not driven by cost savings, but 
rather by a slightly lower (not statistically significant) 
point estimate of efficacy in the ISTp-AL group. The 
results of the PSA including the costs of the health con-
sequences of MiP are shown in Table 4 and Fig. 2a. Per 
1000 women the difference in cost amounted to US$ 
4966.25 (95 % CI US$ 3703.53; 6376.83) more for ISTp-
AL with an excess of 28.36 (95  % CI −75.78; 134.18) 
DALYs. The average ICER from the PSA was −175.12 
(95  % CI −1166.29; 1267.71) US$/DALY averted. The 
results excluding the costs of health consequences of 
Table 2 Itemized cost results
AL arthemether-lumefantrine; HCW health care worker; IP inpatient; IPTp-SP intermittent preventive treatment with sulfadoxine-pyrimethamine; ISTp-AL intermittent 
screening and if positive followed by treatment with artemether-lumefantrine; LBW low birth weight; OP outpatient; SP sulfadoxine-pyrimethamine
a Including freight, insurance, wastage and in country transport
Type of cost Cost parameter Cost in US$ 2012, mean (95 % CI)
Intervention cost Average SP price per administrationa 0.2 (0.16–0.25)
Average AL price per administrationa 2.39 (1.71–3.06)
Average RDT price per administrationa 0.81 (0.58–0.90)
HCW time cost per dose of IPTp-SP 0.59 (0.33–0.91)
HCW time cost per administration of ISTp-AL if screened 
negative
0.64 (0.36–1.00)
HCW time cost per administration of ISTp-AL if screened 
positive
0.84 (0.47–1.31)
Total cost per administration of IPTp-SP (HCW time and com-
modity cost)
0.79 (0.53–1.12)
Total cost per administration of ISTp-AL if screened negative 
(HCW time and commodity cost)
1.45 (1.12–1.85)
Total cost per administration of ISTp-AL if screened positive 
(HCW time and commodity cost)
4.06 (3.29–4.97)
Health provider costs excluding medical supplies Cost per OP visit 11.78 (9.18–14.68)
Cost per IP day adult 35.27 (19.99–55.07)
Cost per paediatric IP day (nursery) 63.51 (36.3–99.27)
Health provider costs of consequences Total average short term cost per LBW baby 40.93 (19.52–71.19)
Total average cost per moderate/severe anaemia case 10.15 (6.76–15.17)
Total average cost per clinical malaria case 13.71 (6.12–24.65)
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MiP are plotted in Fig. 2b yielding a difference in costs of 
US$ 4146.93 (95 % CI 3420.66; 4978.48) per 1000 women 
resulting in an ICER of −146.29 (95  % CI −1039.11; 
1123.15) US$/DALY averted. The less widely dispersed 
simulation points on the CE plane reflect less uncertainty 
around the cost estimate when costs of the health conse-
quences of MiP are excluded.
Cost‑consequences analysis
Table 3 shows the results of the cost-consequences anal-
ysis. Consequences that could not be included in the 
calculation of DALYs included placental malaria, a pri-
mary outcome of the trial, and side effects measured in 
the trial, all expressed as cases per 1000 women. All side 
effects which occurred at statistically significantly differ-
ent rates in the ISTp-AL and IPTp-SP arms are shown. 
Of the measured side effects there were fewer cases of 
dizziness, sleeplessness, weakness, nausea and vomiting 
reported in the ISTp-AL arm. In addition to these meas-
urable differences, there were also other non-measurable 
outcomes that should be considered. These include ben-
efits, such as the intrinsic value of giving fewer drugs to 
pregnant women and only administering drugs to women 
who are infected; the value to women of knowing their 
infection status; and the value to society of identifying 
malaria infection, particularly for surveillance purposes. 
Table 3 Cost consequence analysis 
DALY disability adjusted life years; IPTp-SP intermittent preventive treatment with sulfadoxine-pyrimethamine; ISTp-AL intermittent screening followed by treatment 
with artemether-lumefantrine; LBW low birth weight
a At 24.7 % of administration where RDT showed a positive result
b Costs from consequences = ∑ short term costs LBW baby; costs mod/sev anaemia episode; costs MiP episode
c Clinical malaria defined as illness + positive slide at an unscheduled visit
IPTp‑SP ISTp‑AL
Costs per 1000 pregnant women Health provider excluding consequencesb 
(US$ 2012)
1631.84 (1100.11–2316.97) 5778.77 (4701.65–7039.15)a
Health provider including consequencesb 
(US$ 2012)
9006.54 (5610.30–13,680.56) 13,972.79 (10,199.65–18,983.86)a
Measurable outcomes contributing to 
DALYs per 1000 women [20]
LBW 151 (137–167) 156 (141–172)
severe/moderate anaemia 17 (12–25) 23 (17–32)
clinical malaria (total episodes)c 74 (61–92) 115 (96–144)
Other measurable outcomes per 1000 
women and side effects [20, 37]
Placental malaria: active infection (acute 
and chronic)
245 (224–265) 242 (222–262)
Dizziness 46 (38–54) 25 (19–31)
Sleeplessness 13 (9–17) 7 (4–10)
Weakness 30 (24–37) 18 (13–23)
Nausea 22 (16–28) 13 (9–17)
Vomiting 45 (37–53) 26 (20–32)
Non measurable outcomes Intrinsic value of giving less drugs to pregnant women
Value to individual of knowing about positive test
Value of knowing about positive test for surveillance
Deprivation of treatment for false negatives
Table 4 Cost effectiveness analysis
a Including the costs from health consequences caused by malaria during 
pregnancy
Deterministic results (base case)
 DALYs LBW averted −22.64
 DALYs mod/sev anaemia averted −1.63
 DALYs MiP averted −3.56
 Total DALY IPTp-SP 755.1
 Total DALY ISTp-AL 782.93
 Total cost IPTp-SP (US$ 2012)a 9037.84
 Total cost ISTp-AL (US$ 2012)a 13,966.84
 Δ Costs (US$ 2012)a 4929.00
 Δ DALYs −27.83
 ICER (US$/DALY)a −177.10
Probabilistic results
 DALYs LBW averted −23.15 (−128.35 to 80.71)
 DALYs mod/sev anaemia averted −1.63 (−4.35 to 0.94)
 DALYs MiP averted −3.58 (−5.69 to 1.83)
 Total DALY IPTp-SP 753.55 (631.07 to 895.88)
 Total DALY ISTp-AL 781.91 (657.92 to 928.64)
 Total cost IPTp-SP (US$ 2012)a 9006.54 (5610.30 to 13,680.56)
 Total cost ISTp-AL (US$ 2012)a 13,972.79 (10,199.65 to 18,983.86)
 Δ Costs (US$ 2012)a 4966.25 (3703.53 to 6376.83)
 Δ DALYs −28.36 (−134.18 to 75.78)
 Average ICER (US$/DALY)a −175.12
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There are also potential deleterious effects, such as failure 
to treat women with a false negative test.
Modelling of cost effectiveness for decreasing efficacy 
of SP and decreased commodity costs
Figures 3 and 4 shows the simulation results for a hypo-
thetical reduction of SP efficacy to 50 and 0  % respec-
tively, of the current level. Figures  3a and 4a replicate 
Fig.  2a, while Figs.  3b, c and 4b, c show the simula-
tion results assuming that bed nets bear 1/2 or 2/3 of 
the extrapolated outcome burden when SP efficacy is 
reduced. Simulation results assuming no contribution of 
bed nets can be found in the Additional file 1: Appendix 
S1. By reducing SP efficacy levels from 100 % to 50 % or 
0 %, more simulation points lie in the North Eastern (top 
right) quadrant of the cost effectiveness plane and to the 
right of the WTP threshold (the criterion for being cost-
effective with respect to this threshold). 
Table 5 (in column 2 and 3) indicates the efficacy lev-
els at which ISTp-AL becomes cost effective stratified by 
WTP threshold and the assumptions concerning bur-
den prevented by bed net use. For example at the middle 
WTP threshold ISTp-AL becomes cost-effective when 
the efficacy of IPTp-SP is between (i) 63–64  % or (ii) 
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Fig. 2 Cost effectiveness planes: the graphs display the results of two 
different Monte Carlo simulations with 10’000 iterations each using 
the value ranges and distributions specified in Table 1. The differ-
ent coloured lines illustrate the median and three willingness-to-pay 
(WTP) thresholds. WTP threshold 1 of US$ 861.33 is the GDP/capita 
averaged over the four countries. WTP threshold 2 and 3 represent 
the original thresholds defined by WHO in 1993 as highly attractive 
and attractive, both inflated to US$ 2012. a shows the results includ-
ing the costs occurring from the consequences of malaria during 
pregnancy and b excluding these costs
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Fig. 3 Simulation results: cost effectiveness plane at SP efficacy level 
of 50 % with a bed net coverage of 47.7 % [37] and with costs from 
consequences included. a shows the trial results replicated from 
Fig. 2a for comparison purpose, b, c show the simulation results for 
the assumption that bed nets bear 1/2 and 2/3 respectively, of the 
predicted burden of LBW, severe/moderate anaemia and clinical 
malaria
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59–60 % of current SP efficacy levels, assuming that bed 
nets bear (i) 1/2 or (i) 2/3 of the extrapolated outcome 
burden. For the highest and lowest WTP threshold this 
range lies between 69–73 % and 12–20 %, respectively.
Additional results summarizing the effects of three 
key variables on cost effectiveness: (i) the level of IPTp-
SP efficacy, ranging from 0 to 90 % of current efficacy, (ii) 
bed net coverage and (iii) the WTP threshold are shown 
in the Additional file 1: Appendix S1.
Finally, reducing the costs of ACT and RDT by 
50  % leads to an ICER of US$ −107.7/DALY averted 
(∆Cost = US$ 2998.1, ∆ DALY = −27.8). Table 5 (in col-
umn 4 and 5) shows the results of the threshold analy-
sis when the costs of the ACT and RDT were halved. 
The effect of reducing commodity costs leads to a higher 
threshold of SP efficacy at which ISTp-AL becomes cost 
effective, in other words, with lower commodity costs, SP 
needs to lose less of its efficacy for ISTp-AL to become 
cost-effective.
Discussion
At current levels of cost and efficacy, it is not cost-effec-
tive to switch from IPT-SP to IST-AL in areas where 
Plasmodium falciparum remains sensitive to SP. This is 
because IST-AL is more costly than IPTp-SP and no more 
effective at reducing the adverse effects of malaria dur-
ing pregnancy. However, it is possible to use a cost-effec-
tiveness model to simulate how cost-effectiveness would 
change with the loss of efficacy of IPTp-SP resulting 
from a potential development of SP resistance, and with 
a reduction in commodity costs. The threshold at which 
IST-AL becomes cost effective compared with IPTp has 
been assumed to vary depending on the contribution of 
bed nets to reducing the burden of MiP; another key vari-
able is decision maker WTP to avert a DALY. The analysis 
presented here shows that for the highest WTP threshold 
($861 per DALY averted), ISTp-AL becomes cost-effec-
tive at levels of IPTp efficacy ranging from 69 to 79 % of 
current levels. At a threshold of $238/DALY averted, a 
greater loss of IPTp-SP efficacy is needed for ISTp-AL to 
become cost-effective, and for the lowest threshold ($40/
DALY averted), IPTp-SP efficacy must fall to 12–36 % of 
current levels before IST-AL is more cost-effective. These 
thresholds are higher when commodity costs are halved, 
i.e. this level is found between 71 and 80 % for the highest 
and 35–54 % for the lowest WTP threshold.
The cost-consequences analysis represents an effort to 
introduce into the decision-making metrics the effects 
of important consequences that cannot be readily incor-
porated into the calculation of DALYs. For example, as 
malaria incidence diminishes, the justification for pre-
sumptive treatment will need to be re-examined, however 
safe the drug used for preventive treatment. Valuations of 
this benefit could be elicited from women and commu-
nities. However, integrating this benefit into outcome 
measures may require moving to a cost-benefit or impact 
evaluation framework. Similarly, the value of information 
on infection, either to women individually or as a con-
tribution to surveillance in a context of malaria elimina-
tion, could be examined empirically. On the other hand 
there is also the possible negative impact of women who 
falsely test negative, who could potentially be deprived 
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Fig. 4 Simulation results: cost effectiveness plane at SP efficacy level 
of 0 % with a bed net coverage of 47.7 % [37] and with costs from 
consequences included. a shows the trial results replicated from 
Fig. 2a for comparison purpose, b, c show the simulation results for 
the assumption that bed nets bear 1/2 and 2/3 respectively, of the 
predicted burden of LBW, severe/moderate anaemia and clinical 
malaria
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of essential treatment. However, for the purpose of this 
analysis the authors have elected to enumerate, rather 
than to quantify, these benefits or disadvantages.
This analysis is subject to a number of important limi-
tations. First, the Cochrane review [30] includes results 
from more recent trials, including some conducted in 
areas where some level of SP resistance is expected, bias-
ing downwards the efficacy of IPT-SP prior to the simu-
lated decrease due to resistance. Second, the presence of 
bed nets introduces a series of complications related to 
distinguishing the incremental effect of IPTp-SP when 
bed nets are already addressing some share of the burden 
of MiP. The Cochrane review efficacy estimates were not 
stratified by bed net use, therefore assumptions about the 
incremental effectiveness of IPTp-SP in addition to bed 
nets were needed. All trial participants were given a bed 
net but actual adherence to bed nets was not measured 
and, therefore, it was not possible to stratify efficacy by 
bed net use, although it is expected to have been high 
under trial conditions.
The costs of ISTp-AL were affected by the propor-
tion of women who test positive when screened with an 
RDT, which in turn is dependent on malaria transmission 
intensity. However, even at the lowest observed level of 
positive test results, ISTp-AL was not cost-effective as the 
cost of the test itself exceeds that of IPTp-SP.
Costs also depend on the number of times a woman 
receives each intervention during a pregnancy. At the 
time of the trial, the policy in three of the trial coun-
tries was for women to receive two doses of IPTp-SP, 
resulting as measured in the trial in 2.06 administra-
tions per woman in the IPTp-SP and 2.76 in the ISTp-
AL arm. Although it would be feasible to explore how 
the frequency of administration would affect costs, it is 
impossible to estimate how this would influence efficacy, 
therefore trial estimates were used. As an indication, 
increasing the number of administrations of IPTp-SP to 
2.76 per woman reduced the difference in costs between 
the two interventions to US$ 4.4 per woman. Transmis-
sion level is also likely to influence cost-effectiveness. 
More evidence is needed from low transmission settings, 
which also partially overlap with sextuple mutant settings 
as to how this balance will work out.
This model has focused on simulating how cost effec-
tiveness of ISTp-AL changes if SP efficacy decreases. It 
is currently not known how SP resistance levels trans-
late into IPTp efficacy and ISTp has yet to be shown to 
be more effective in a high resistance setting. One trial 
conducted in Western Kenya, where the prevalence of 
the sextuple A581G mutant was measured at 5.8 %, found 
ISTp with dihydroartemisinin–piperaquine (DP) to be 
inferior to IPTp-SP [13]. It is thought that in settings with 
even higher prevalence of the A581G sextuple mutant, 
IPTp-SP has almost no efficacy in preventing clinical 
malaria, MiP attributable LBW and anaemia [14, 15], 
however the loss of SP efficacy in such settings remains 
to be studied. Naidoo and Roper suggested that most P. 
falciparum resistance patterns appear first in East Africa 
and usually spread to Central and West Africa within 
15 years [31].
Decisions about a change in strategy to prevent MiP 
will be based on many factors in addition to effectiveness 
and cost-effectiveness. Feasibility and acceptability to 
mothers and health workers will be important, as will be 
the feasibility of policy change. In addition, total cost and 
affordability will be crucial.
Table 5 Threshold modelling for decreasing SP efficacy: Efficacy levels of IPTp-SP at which ISTp-AL becomes cost effective 
stratified by (1) two assumptions made on burden prevented by bed net use at a bed net coverage of 47.7 % and (2) will-
ingness to pay threshold
Results are shown for the full costs of RDT and AL as well as for the costs reduced by 50 %
The first column shows the three willingness to pay (WTP) thresholds
The first row indicates if the full costs for RDT and AL were used or if they were halved
The second row of the table show the two assumptions made regarding burden prevented by bed net use with bed nets bearing 1/2 and 2/3 respectively of the 
extrapolated burden of LBW, severe/moderate anemia and clinical malaria when IPTp-SP efficacy decreases Results shown here are based on a 47.7 % bed net 
coverage level
Full costs of RDT and AL Costs of RDT and AL halved
Bed nets bear 1/2 
of extrapolated burden
Bed nets bear 2/3 
of extrapolated burden
Bed nets bear 1/2 
of extrapolated burden
Bed nets bear 2/3 
of extrapolated burden
WTP 1 = US$ 861.33/DALY 
averted
Between 72 and 73 % Between 69 and 70 % Between 74 and 75 % Between 71 and 72 %
WTP 2 = US$ 238.33/DALY 
averted
Between 63 and 64 % Between 59 and 60 % Between 68 and 69 % Between 65 and 66 %
WTP3 = US$ 39.72/DALY 
averted
Between 19 and 20 % Between 12 and 13 % Between 41 and 42 % Between 35 and 36 %
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Conclusion
At the current level of SP efficacy and transmission inten-
sity found in this trial in West Africa, switching from 
IPTp-SP to ISTp-AL is not recommended as ISTp-AL 
is not more effective and costs considerably more per 
woman. However, as our modelling suggests, in settings 
with  >10  % prevalence of the sextuple mutant, where 
IPTp has reduced or no efficacy, ISTp-AL has the poten-
tial to be a viable and cost-effective option. Any contin-
ued decrease in commodity costs would positively affect 
this transition.
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